Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors.
Yoshikawa Y, Imamura M, Yamauchi M, Hayes CN, Aikata H, Okamoto W, Miyata Y, Okada M, Hattori N, Sugiyama K, Yoshioka Y, Toratani S, Takechi M, Ichinohe T, Ueda T, Takeno S, Kobayashi T, Ohdan H, Teishima J, Hide M, Nagata Y, Kudo Y, Iida K, Chayama K.
Yoshikawa Y, et al. Among authors: okada m.
BMC Cancer. 2022 Nov 29;22(1):1232. doi: 10.1186/s12885-022-10327-7.
BMC Cancer. 2022.
PMID: 36447159
Free PMC article.